This view is based on the evidence, discussed above, that measures of brain atrophy, despite methodological limitations, appear to be a clinically useful marker of neuroaxonal damage in MS; indeed, early brain atrophy has recently been shown to be predictive of response to IFN-β treatment [91]. Here, IFNB1 is linked to Brain atrophy.